VistaGen Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell VTGN and other ETFs, options, and stocks.About VTGN
VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia).
CEOShawn K. Singh
CEOShawn K. Singh
Employees33
Employees33
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded1998
Founded1998
Employees33
Employees33
VTGN Key Statistics
Market cap128.78M
Market cap128.78M
Price-Earnings ratio-1.35
Price-Earnings ratio-1.35
Dividend yield—
Dividend yield—
Average volume178.65K
Average volume178.65K
High today$4.86
High today$4.86
Low today$4.65
Low today$4.65
Open price$4.71
Open price$4.71
Volume194.53K
Volume194.53K
52 Week high$24.71
52 Week high$24.71
52 Week low$1.62
52 Week low$1.62
VTGN News
Seeking Alpha 3d
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression - Seeking AlphaKlaus Vedfelt/DigitalVision via Getty Images I haven't written about Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in five years, but following some interesting re...
